

## 1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Rebastinib

Product Number : 10-4689

Brand : Focus Biomolecules

CAS-No. : 1020172-07-9

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting PA, 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : CHEMTREC within USA/Canada 1-800- 424-9300

CHEMTREC outside USA/Canada 1-703-527-3887

# 2. HAZARDS IDENTIFICATION

#### 2.1 Classification of the substance or mixture

# GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, Oral (Category 4), H302

Skin corrosion/irritation (Category 2), H315

Serious eye damage/eye irritation (Category 2A), H319

Specific target organ toxicity, single exposure; Respiratory system (category 3), H335

For the full text of the H-Statements mentioned in this Section, see Section 16.

## GHS Label elements, including precautionary statements

Pictogram

Signal word

Warnin

Hazanrd statement(s)

H302 Harmful if swallowed. H315 Causes skin irritation

H319 Causes serious eye irritation H335 May cause respiratory irritation

Precautionary statement(s)

P261 Avoid breathing dust/fume/gas/mist/vapors/spray

P305 + P351 IF IN EYES: Rinse with water for sever minutes. Remove contact lenses if possible

Rebastiniib Page 1 of 7

# 2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

## 3.1 Substances

Synonyms : 4-(4-(3-(3-(tert-Butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-

yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide

Formula :  $C_{30}H_{28}FN_7O_3$ Molecular weight : 553.59 g/mol CAS-No. : 1020172-07-9

**Hazardous components** 

Component	Classification	Concentration
Rebastinib		
	Acute Tox. 4, H302; Skn. 2,	90 - 100 %
	H315; Eye, 2A, H319;	

For the full text of the H-Statements mentioned in this Section, see Section 16.

## 4. FIRST AID MEASURES

# 4.1 Description of first aid measures

#### Eve contact

Remove contact lenses if present. Flush open eyes with large amount of water. Promptly call physician

#### If inhaled

If breathed in, move into fresh air. If not breathing, give artificial respiration. Consult a physician.

#### In case of skin contact

Rinse throughly with large amounts of water. Remove contaminated clothing. Consult a physician.

## If swallowed

Rinse mouth with water. Do NOT induce vomiting Consult a physician.

# 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in section 11

# 4.3 Indication of any immediate medical attention and special treatment needed

No data available

# 5. FIREFIGHTING MEASURES

# 5.1 Extinguishing media

# Suitable extinguishing media

Use alcohol-resistant foam, dry chemical or carbon dioxide.

## 5.2 Special hazards arising from the substance or mixture

During combustion may emit toxic fumes

## 5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

## 5.4 Further information

No data available

Rebastinib Page 2 of 7

#### 6. ACCIDENTAL RELEASE MEASURES

# 6.1 Personal precautions, protective equipment and emergency procedures

Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

#### **6.2** Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains or water courses.

## 6.3 Methods and materials for containment and cleaning up

Bind, pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

#### Reference to other sections

**6.4** For disposal see section 13.

## 7. HANDLING AND STORAGE

## 7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

## 7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20°C

# 7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### 8.1 Control parameters

## Components with workplace control parameters

Contains no substances with occupational exposure limit values.

## 8.2 Exposure controls

# Appropriate engineering controls

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

#### Personal protective equipment

# Eye/face protection

Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

## Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

#### **Body Protection**

Wear protective clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

# Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate, use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Rebastiniib Page 3 of 7

## Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

#### 9.1 Information on basic physical and chemical properties a)

Form: solid Appearance b) Odor No data available Odor Threshold No data available d) No data available Melting point/freezing No data avaialble e) point Initial boiling point and No data available boiling range No data available Flash point Evaporation rate No data available h) Flammability (solid, gas) No data available i) Upper/lower No data available flammability or explosive limits Vapor pressure No data available No data available Vapor density 1) m) Relative density No data available Water solubility No data available n) Partition coefficient: n-No data available octanol/water Auto-ignition No data available temperature Decomposition No data available

temperature

No data available Viscosity r) Explosive properties No data available s) Oxidizing properties No data available t)

#### 9.2 Other safety information

No data available

# 10. STABILITY AND REACTIVITY

#### 10.1 Reactivity

No data available

#### 10.2 Chemical stability

Stable under recommended storage conditions.

#### 10.3 Possibility of hazardous reactions

No data available

#### 10.4 Conditions to avoid

No data available

#### 10.5 **Incompatible materials**

Strong oxidizing agents

#### 10.6 Hazardous decomposition products

Rebastinib Page 4 of 7 Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen fluoride

# 11. TOXICOLOGICAL INFORMATION

## 11.1 Information on toxicological effects

Acute toxicity No data available

Inhalation: No data available Dermal: No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitization

No data available

Germ cell mutagenicity

No data available

# Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable,

possible or confirmed human carcinogen by IARC.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known

or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of

regulated carcinogens.

Reproductive toxicity

No data available.

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

**Additional Information** 

Chemical, physical, and toxicological properties have not been completely investigated

Rebastinib Page 5 of 7

# 12. ECOLOGICAL INFORMATION

# 12.1 Toxicity

No data available

## 12.2 Persistence and degradability

No data available

# 12.3 Bioaccumulative potential

No data available

## 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

#### 12.6 Other adverse effects

No data available

# 13. DISPOSAL CONSIDERATIONS

## 13.1 Waste treatment methods

#### Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

## Contaminated packaging

Dispose of as unused product.

# 14. TRANSPORT INFORMATION

## DOT (US)

UN number: 2811 Class: 6.1 Packing group: III

Proper shipping name: Toxic solids, organic, n.o.s. (Rebastinib)

Reportable Quantity (RQ): Poison Inhalation Hazard: No

**IMDG** 

UN number: 2811 Class: 6.1 Packing group: III EMS-No: F-A, S-A

Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (Rebastinib)

**IATA** 

UN number: 1544 Class: 6.1 Packing group: III

Proper shipping name: Toxic solids, organic, n.o.s. (Rebastinib)

# 15. REGULATORY INFORMATION

# **SARA 302 Components**

This material does not contain any components with a section 302 EHS TPQ.

#### **SARA 313 Components**

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## SARA 311/312 Hazards

No SARA Hazards

# Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

### Pennsylvania Right To Know Components

No components are subject to the Pennsylvania Right to Know Act

Rebastinib Page 6 of 7

# California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

# 16. OTHER INFORMATION

## **Further information**

Copyright 2024 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 12/20/2024

Rebastinib Page 7 of 7